Vertex Pharmaceuticals’ non-opioid pain medication gets FDA approval

A non -opioid pain medication taken by Vertex Pharmaceuticals has received approval from adults from Food and Drug Administration (FDA).

The Société “first in class” of the company analgesic I received the green light for treated moderate to severe acute pain in adults on Thursday, the federal agency said.

The drug reduces pain “by targeting a pain in pain involving sodium channels in the peripheral nervous system, before pain signals reach the brain The FDA.

Green Pharmaceuticals logo on a smartphone. (Pavlo Gonchar / Sopa Images / Lightrocket via Getty Images / Getty Images)

He will use daily as a brand name.

Get Fox Affairs on the move by clicking here

The CEO of Vertex, Reshma Kewalramani, presented Jouravx as the “first new class of pain medicine approved in more than 20 years”, adding that the company has “the opportunity to change the paradigm of acute pain management and establish a new standard of care “.

The drug has led to a “statistically significant” pain reduction compared to a placebo within two days for patients in a pair of trials that had received abdominoplastic and oinionctomies, according to Vertex. The trials were randomized, double -blind, controlled by placebo and controlled by Actif.

“A new non -opioid analgesic therapeutic class for acute pain offers the opportunity to alleviate certain risks associated with the use of an opioid for pain and offers patients another Treatment option“The Director of the Evaluation of Medicines and the Research of the Center of the FDA, Dr. Jacqueline Corrigan-Curay, said.” This action and the appointment of the agency to accelerate the development and examination of the drug underline the commitment of the FDA to approve of safe and effective alternatives to opioids for pain management. “”

A sign for the Food and Drug Administration outside the agency’s headquarters in White Oak, Maryland. (Sarah Silbiger / Getty Images / Getty Images)

Vertex said that almost 10% of patients initially gave opioids to soothe acute pain ultimately using opioids, which can be addictive, for a prolonged time.

Wegovy, the weight loss medication, obtains FDA approval for use as a heart disease prevention medication

The cost of wholesale acquisition of Jouravx compared to $ 15.50 will be $ 15.50, according to the company.

The FDA said that suzetrigine was “contraindicated” for people using “strong CYP3A inhibitors”. It is also informed that patients taking the non -opioid drug from Vertex do not eat or drink nothing containing grapefruit.

After the announcement of the Jouravx reception of FDA approval, Vertex saw gains in its stock market, its shares displaying more than 5% of 5% on Friday. Its market capitalization, on the other hand, oscillated about $ 119.81 billion in the afternoon.

Click here to find out more about Fox Business

The company said it was also considering applications of peripheral neuropathic pain for the drug.

Vertex has been in business since the late 1980s. Six of the other company’s drugs are currently approving the FDA, according to its website.